NCT03334708Recruiting
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 1 Nov 2017
- Start date
- 30 Oct 2017
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Pancreatic cancer
- NCT number
- NCT03334708
What you commit to
- Study type: Observational
- Planned participants: 120
- From 30 Oct 2017 to the primary completion date, 30 Oct 2026
- 13 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting
- Neoadjuvant chemotherapy or radiation therapy is planned
- IPMN with high risk features or planned resection
Other illness
- Cohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria
- Active second malignancy, unless low grade malignancy
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria
- Active second malignancy, unless low grade malignancy
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 5: IPMN Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 6: Pancreatic Cyst Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 7: Healthy Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Who the study is looking for
- Cohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria
- Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution
- Patient planning to receive systemic treatment
- Hemoglobin \> 8
- ECOG performance status 0-2
- A minimum age of 18 years old
- Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
- Cohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria
- Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution
- Patient planned to undergo upfront resection
- No pre-operative systemic therapy nor chemoradiation therapy planned
- Hemoglobin \> 8
- ECOG performance status 0-2
- A minimum age of 18 years old
- Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
- Cohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria
- Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution
- Hemoglobin \> 8
- ECOG performance status 0-2
- A minimum age of 18 years old
- Cohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria
- Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution
- Hemoglobin \> 8
- ECOG performance status 0-2
- A minimum age of 18 years old
- Cohort 5: IPMN Control Inclusion Criteria
- Confirmed diagnosis of IPMN without high risk features by the enrolling institution
- A minimum age of 18 years old
- Cohort 6: Pancreatic Cyst Control Inclusion Criteria
- Confirmed diagnosis of benign pancreatic cyst by the enrolling institution
- A minimum age of 18 years old
- Cohort 7: Healthy Control Inclusion Criteria
- A minimum age of 18 years old
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sha'are Zedek Medical Center Coordinator of this site? Confirm its status | Jerusalem | Israel | Not yet recruiting |
| Weizmann Institute of Science Coordinator of this site? Confirm its status | Rehovot | Israel | Not yet recruiting |
| Sheba medical center Coordinator of this site? Confirm its status | Tel HaShomer | Israel | Recruiting |
| Cold Springs Harbor Laboratory (Specimen Analysis) Coordinator of this site? Confirm its status | Cold Spring Harbor | United States | Not yet recruiting |
| Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities) Coordinator of this site? Confirm its status | Commack | United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) Coordinator of this site? Confirm its status | Harrison | United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) Coordinator of this site? Confirm its status | Middletown | United States | Recruiting |
| Memorial Sloan Kettering Bergen (All Protocol Activities) Coordinator of this site? Confirm its status | Montvale | United States | Recruiting |
| New York University Coordinator of this site? Confirm its status | New York | United States | Active, not recruiting |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (All protocol activities) Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Weill Cornell Medical Center Coordinator of this site? Confirm its status | New York | United States | Not yet recruiting |
| Memorial Sloan Kettering Nassau (All Protocol Activities) Coordinator of this site? Confirm its status | Rockville Centre | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.